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ABSTRACT
JAK1 frameshift mutations may promote cancer cell immune evasion by 
impeding upregulation of the antigen presentation pathway in microsatellite unstable 
endometrial cancers (ECs). This study investigated the JAK1 mutation frequency, 
its functional implication in immune evasion and its prognostic significance in 
microsatellite unstable EC. Microsatellite instability and three microsatellite repeats 
within JAK1 were analyzed in 181 ECs. Sixty-two (34%) ECs showed microsatellite 
instability, of which 22 (35%) had a JAK1 mutation. LMP7, TAP1 and HLA class I 
protein expression and the presence of CD8-positive T-cells were analyzed in the 
microsatellite unstable ECs. JAK1 mutant microsatellite unstable ECs showed impaired 
upregulation of LMP7 (P=0.074) and HLA class I (P<0.001), validated using RNAseq 
data of the TCGA. TAP1 expression and presence of CD8-positive T-cells were not 
related to JAK1 mutations. In 198 additional microsatellite unstable ECs, the JAK1 
mutation frequency was confirmed but no prognostic significance was found. For, 
JAK1 wildtype (n=135, 72%) and mutant (n=52, 28%) ECs, 10-year recurrence free 
rates were 84% and 77% (P=0.301). These observations show that JAK1 mutations 
are highly frequent in microsatellite unstable EC, not associated with survival, but 
are associated with impaired upregulation of LMP7 and HLA class I and may therefore 
facilitate immune escape.
INTRODUCTION
About 30% of endometrial cancers, predominantly 
of endometrioid histology, can be molecularly 
characterized by microsatellite instability (MSI). MSI 
is a hypermutable phenotype caused by the loss of 
DNA mismatch repair (MMR) activity mostly due 
to sporadic MLH1 promoter hypermethylation [1]. 
Tumors that exhibit this phenotype have numerous 
insertions and deletions also in coding microsatellites 
causing frameshift mutations and loss of protein 
function. The coding microsatellite-containing genes 
frequently affected by MSI are believed to be involved 
in progression of MSI tumors [2]. Some target genes, 
such as BAX, are altered in diverse MSI tumor types 
(e.g. colorectal- and ovarian cancer), whereas others, 
such as JAK1, have a very restricted occurrence in MSI 
endometrial cancers [3-6]. MSI endometrial cancers 
show a remarkably high number of JAK1 frameshift 
mutations that may have clinical implications [4, 5].
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JAK1 plays a role in the JAK/STAT pathway, which 
is activated by cytokines such as IFNγ, that influence 
several cellular processes such as cell growth and 
immune response [7-9]. Ren et al. have shown that JAK1 
mutant gynecological cancer cell lines were defective 
in interferon gamma (IFNγ) induced STAT1 tyrosine 
phosphorylation and thereby impede upregulation of 
antigen processing machinery components such as 
LMP2 and TAP1 [10]. Impaired antigen processing and 
presentation due to hindered expression of LMP and/
or TAP proteins are associated with lack of HLA class I 
upregulation and resistance to cytotoxic T-cell mediated 
lysis [11, 12]. HLA class I expression has been reported 
as a prognostic marker in endometrial cancer patients 
[13-15] and upregulation of HLA class I was frequently 
impaired in MSI endometrial cancers [14, 16]. The high 
rate of JAK1 mutations in MSI endometrial cancer is 
suggestive of an adaptation favoring tumor survival by 
blocking the JAK/STAT pathway activity, and impeding 
an adequate immune response.
MSI tumors exhibit a high number of somatic 
mutations that could facilitate an immune response by 
presentation of neo-antigen-epitopes in the context of 
HLA class I molecules. Programmed death 1 expressed 
on cytotoxic T-cells is a checkpoint involved in immune 
suppression. Checkpoint inhibitors, as potential 
mechanism for T-cell activation, recently showed 
promising results in treatment of mismatch repair deficient 
tumors independent of tumor origin [17]. However, JAK1 
mutations and other mechanisms involved in impeding 
antigen presentation and expression of antigen processing 
machinery components in MSI endometrial cancers may 
interfere with new treatment regiments for MSI tumors 
such as the programmed death 1 inhibitor pembroluzimab. 
[17, 18].
In this study, MSI and JAK1 mutation status were 
analyzed in a study cohort of 181 tissue samples of 
endometrial cancer patients with the aim to evaluate that 
the JAK1 locus is frequently affected by MSI, and to 
determine its functional implication in immune evasion 
by analyzing expression of antigen presenting machinery 
components and the presence of cytotoxic T-cells 
specifically in MSI endometrial cancers. Finally, the 
effect of JAK1 mutation status on survival was evaluated 
in a large independent cohort of 198 MSI endometrial 
cancer patients with mature long-term follow-up from the 
PORTEC-1 and -2 clinical trials [19, 20].
RESULTS
Of the 181 endometrial cancers from the study 
cohort, MSI was detected in 62 (34%) cases, in nine cases 
MSI status remained unclear due to technical failure. 
Twenty-two (35%) MSI endometrial cancers had a JAK1 
frameshift mutation, mainly at position K860, whereas 
only 3 of 110 (3%) MSS endometrial cancers had a JAK1 
mutation (P<0.001, Supplementary Table S1). Two of 
these three JAK1 mutant MSS cases showed focal loss of 
MLH1 protein expression in part of the tumor as a result 
of MLH1 promoter hypermethylation. There were no 
significant differences in age, FIGO stage, differentiation 
grade or tumor type between JAK1 wildtype and mutant 
MSI endometrial cancers (Table 1). However, JAK1 
mutations were associated with deeper myometrial 
invasion (P=0.030; odds ratio 3.500, 95% confidence 
interval 1.102-11.116).
The functional implication of JAK1 in tumor 
immune evasion was analyzed by expression analysis 
of TAP1, LMP7, HLA class I and presence of CD8-
positive T-cells in the MSI endometrial cancers (Table 2). 
Distribution of TAP1 expression was similar for both 
JAK1 wildtype and mutant (P=0.151). Upregulation of 
LMP7 was impaired in JAK1 mutant tumors, although 
not statistically significant (P=0.074). Upregulation of 
HLA class I was significantly impaired in JAK1 mutant 
tumors (P<0.001). The expression of HLA class I was 
related to LMP7 expression in contrast to TAP1 (P=0.001 
vs. P=0.381). Presence of CD8-positive T-cells was not 
related to JAK1 mutation (Figure 1).
In order to validate these findings in an independent 
cohort, RNAseq data was used from 25 TCGA MSI 
endometrial cancers with analyzed DNA slippage events. 
The 13 JAK1 mutant endometrial cancers showed 
significantly lower expression of TAP1 (2.1-fold, 
P<0.001), LMP7 (3.0-fold, P<0.001), and HLA class 
I (2.5-fold, P<0.001) in comparison to JAK1 wildtype 
endometrial cancers (Figure 2). Consistent with the results 
in our study cohort, JAK1 mutation status did not correlate 
with CD8 expression (P=0.112).
Two patient cohorts derived from the PORTEC-1 
and -2 randomized trials with MSI early-stage endometrial 
cancers (n=198) with long-term mature follow-up data 
were used to investigate a possible prognostic effect of 
JAK1 frameshift mutations. In this independent cohort, 
fifty-two (28%) of MSI endometrial cancers had a JAK1 
mutation (Supplementary Table S1). No significant 
differences were found between JAK1 mutation status and 
clinicopathological characteristics, and the association of 
JAK1 mutation and deep myometrial invasion could not be 
confirmed (Table 1). This discrepancy could be explained 
by the fact that this cohort consisted of significant more 
tumors with deep myometrial invasion compared to 
the study cohort (Supplementary Table S2). For JAK1 
wildtype and mutant endometrial cancers, 10-year 
recurrence free rates were 84% versus 77%, respectively 
(P=0.301) and 10-year overall survival was 64.4% and 
63.5% (P=0.716) (Figure 3). Neither did subanalysis 
(e.g. in grade 3 cancers, or when analyzing only pelvic 
and distant recurrences) show a significant difference in 
outcome between JAK1 wildtype and mutant endometrial 
cancer patients. Survival analysis within the TCGA 
microsatellite unstable endometrial cancers with known 
Oncotarget39887www.impactjournals.com/oncotarget
Table 1: Clinicopathological characteristics of 58 MSI endometrial cancers of the study cohort and 187 MSI 
endometrial cancers of the PORTEC cohort according to JAK1 mutation status











  <60 years 18 (50.0) 11 (50.0) 19 (14.1) 7 (13.5)
  >60 years 18 (50.0) 11 (50.0) 116 (85.9) 45 (86.5)
Tumor type 0.430 0.534
  Endometrioid 35 (97.2) 22 (100) 134 (99.3) 52 (100)
  Serous 1 (2.8) 0 (0.0) 1 (0.7) 0
FIGO (2009)* 0.650 0.270
  I 22 (61.1) 11 (52.4) 135 (100) 52 (100)
  II 3 (8.3) 4 (19.0) 0 0
  III 10 (27.8) 5 (23.8) 0 0
  IV 1 (2.8) 1 (4.8) 0 0
Grade 0.885 0.725
  1 13 (36.1) 7 (31.8) 77 (57.0) 33 (63.5)
  2 14 (38.9) 10 (45.5) 31 (23.0) 10 (19.2)
  3 9 (25.0) 5 (22.7) 27 (20.0) 9 (17.3)
Myometrial 
invasion* 0.030 0.172
  <50% 21 (55.3) 6 (28.6) 45 (33.3) 12 (23.1)
  >50% 15 (41.7) 15 (71.4) 90 (66.7) 40 (76.9)
* 1 missing value in the study cohort
Table 2: Expression of antigen processing machinery components TAP1, LMP7 and HLA class I in JAK1 wildtype 
and mutant MSI endometrial cancers
JAK1 wildtype n=36 
(62.1%)




  Impaired/Normal 24 (68.6) 18 (85.7)
  Upregulated 11 (31.4) 3 (14.3)
LMP7* 0.074
  Impaired/Normal 8 (22.9) 10 (45.5)
  Upregulated 27 (77.1) 12 (54.5)
HLA class I <0.001
  Impaired 7 (19.4) 12 (54.5)
  Normal 3 (8.3) 6 (27.3)
  Upregulated 26 (72.2) 4 (18.2)
* 1 missing value
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JAK1 mutation status (n=30) showed neither a survival 
benefit for JAK1 wildtype tumors (data not shown).
DISCUSSION
This research shows that frameshift mutations in 
JAK1 frequently and almost exclusively occur in MSI 
endometrial cancers. JAK1 mutations were associated with 
impaired upregulation of antigen presenting machinery 
proteins LMP7 and HLA class I. The association of 
JAK1 mutations with limited expression of the antigen 
presentation pathway was validated using RNAseq 
data of the TCGA MSI endometrial cancers. Impaired 
upregulation of HLA class I expression interferes with 
Figure 2: Heatmap of RNA expression of genes encoding for antigen machinery components. Case numbers 1-12 represent 
JAK1 wildtype and 13-25 JAK1 mutant MSI endometrial cancers. A broader analysis independent of MSI status was previously shown by 
Kim et al.
Figure 1: Quantification of CD8-positive T-cells in intraepithelial and intrastromal components in the center of the 
tumor (CT) and invasive margin (IM) in JAK1 wildtype (WT) and mutant (MUT) MSI endometrial cancers.
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tumor lysis by cytotoxic T-cells, and therefore JAK1 
mutations may facilitate an immune escape. However, no 
effect was observed of JAK1 mutation status on recurrence 
rate and overall survival in a large independent cohort of 
198 MSI endometrial cancers. These findings suggest a 
functional role for JAK1, although with no prognostic 
value which suggests that JAK1 mutations are pivotal 
to cancer initiation and/or maintenance, in an intriguing 
tissue-specific manner.
The overall JAK1 mutation frequency of 28% in 
our large series of MSI endometrial cancers is in line 
with findings from two recent smaller studies [4, 5]. Both 
studies also showed that JAK1 frameshift mutations in MSI 
tumors are tissue specific and significantly less important 
in colorectal cancers as compared with endometrial 
cancers. Similarly, Ren et al. identified JAK1 frameshift 
mutations mainly in gynecological cancers, primarily in 
endometrial and cervical cancer, when sequencing more 
than 3,000 tumors from various human tissues [10]. 
Altogether, the occurrence of JAK1 mutation specifically 
in endometrial cancer is suggestive of a positive selection 
for this mutation in endometrial cancer.
To date, there is very little evidence for the 
functionality of JAK1 frameshift mutations in endometrial 
cancer. An in vitro study with one endometrial cancer 
and two ovarian cancer cell lines harboring JAK1 
frameshift mutations demonstrated that JAK1 mutations 
impede STAT1 posphorylation and upregulation of 
antigen presenting machinery components LMP2 and 
TAP1 [10]. Kim et al. have shown that JAK1 mutations 
were associated with hampered JAK/STAT signaling 
and lymphocyte activation [4]. These findings suggest 
that JAK1 mutations have a negative effect on tumor 
immune surveillance. Our study now confirmed impaired 
upregulation of LMP7 and HLA class I with no effect on 
TAP1 expression and the number of CD8-positive T-cells 
in JAK1 mutant endometrial cancer tissue samples. The 
findings on protein expression were validated using 
RNAseq data of TCGA MSI endometrial cancers, except 
for TAP1. TAP1 gene expression may not be equal to 
its protein expression because of the small number of 
cases with RNAseq data (n=25) or due to the (post-)
translational process into proteins. The lack of correlation 
between JAK1 mutations and CD8-positive T-cells might 
be explained by the fact that recruitment and migration of 
T-cells do not rely on recognition of peptides presented by 
HLA class I molecules. In addition, previous studies have 
also shown a high correlation between LMP7 expression 
and HLA class I expression, but not with LMP2 or 
TAP1/2 [21, 22]. This further strengthens the argument 
that JAK1 mutations favor immune escape via the JAK/
STAT signaling, although, this study did not evaluate the 
activation status of the JAK/STAT signaling by phospho-
STAT1 expression.
The association of JAK1 mutations and lack of HLA 
class I upregulation in MSI endometrial cancers with no 
effect on clinical course was an unanticipated finding of 
our study. Bijen et al. and Yakabe et al. reported impaired 
upregulation of HLA class I as a prognostic marker for 
survival in endometrial cancer patients [13, 15]. Of note, 
Figure 3: Clinical outcome of 198 MSI endometrial cancer stratified by JAK1 mutations status. A. Overall recurrence rate 
and B. Overall survival. WT= wildtype; MUT=mutant.
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a large proportion of HLA class I negative endometrial 
cancers are MSI [14]. , therefore, separate analysis of MSI 
and MSS tumors would be of interest to determine the 
prognostic impact of HLA class I. This study indirectly 
showed no effect of HLA class I expression on survival via 
the JAK1 mutation status in a large cohort of MSI, early-
stage endometrial cancers. HLA class I expression was not 
analyzed on the precious PORTEC tissue samples as this 
will only validate previous findings of Ren et al., the study 
and TCGA cohort and the fact that JAK1 mutations have 
no effect on survival will remain. However, the relatively 
good prognosis of this cohort of early-stage cancers 
needs to be taken into account. The previous studies 
were performed in heterogeneous groups of endometrial 
cancers consisting of different histologic subtypes and 
different FIGO stages [13-15]. Therefore, the prognostic 
role remains to be determined in higher risk endometrial 
cancers. These results, in contrast to the finding that JAK1 
mutations favor immune evasion, may suggest a lack 
of negative selection of JAK1 mutations specifically in 
endometrial cancer.
Considering the process of immune surveillance 
in cancer [11, 12]. , it is likely that JAK1 mutant tumors 
are still recognizable to cells of the innate immune 
system (natural killer cells) or that JAK1 wildtype 
tumors have encountered other mechanisms to evade 
immune-mediated killing. However, low numbers of 
natural killer cells that lack an association with HLA 
class I expression were observed in endometrial cancer 
(unpublished data by Versluis et al.). On the contrary, 
IFNγ production might be responsible for a CD4-positive 
T-cell-mediated antitumor immunity [23]. ].  Furthermore, 
JAK1 wildtype tumors may not demonstrate a survival 
benefit because of other strategies to dampen immune 
response such as upregulation of anti-apoptotic molecules, 
expression of immune-inhibitory ligands or secretion of 
immunosuppressive cytokines. Nevertheless, our findings 
imply that JAK1 mutations may exert in part its oncogenic 
effects by immune escape, but we cannot exclude other 
contributions of JAK1 in the JAK/STAT signaling [7].
Better understanding of the antigen-specific immune 
responses and tumor microenvironment may guide 
immunotherapy. Recently, immune checkpoint blockade 
were reported as promising therapies for tumors with a 
high mutational load, including mismatch repair deficient 
endometrial cancers, as a result of an increased neo-
antigen specific T-cell response [17]. JAK1 mutations in 
MSI endometrial cancers may interfere with the T-cell 
response due to impaired HLA class I or PD-L1 expression 
[17, 18]. In melanoma, one patient without a clinical 
response to PD-1 blockade and increased T-cell response 
showed a loss of function JAK1 mutation that unables 
PD-L1 upregulation. All other fifteen melanoma patients 
did not show genetic alterations in the interferon receptor 
signaling pathway [18]. These limited data suggest 
that JAK1 mutations may be used as negative selective 
predictive biomarker for immune blockade therapy. 
However, additional studies are required on the immune 
microenvironment of JAK1 mutant endometrial cancers 
(e.g. PD-L1 expression).
We have identified a high frequency of JAK1 
mutations in MSI endometrial cancers in two relatively 
large series of MSI endometrial cancers. In addition, JAK1 
mutations may have a negative effect on tumor immune 
surveillance due to lack of HLA class I upregulation on 
the cell surface. It must be noted that it remains unclear 
why JAK1 mutations are limited to gynecological cancers 
and mainly to MSI endometrial cancer. However, B2M 
frameshift mutations, also leading to immune escape 
via loss of HLA class 1 expression, frequently occur in 
MSI colorectal cancer and are a rare phenomenon in MSI 
endometrial cancer [14, 24]. In addition, Xiong et al. 
showed that JAK1 inhibition is associated with cell cycle 
arrest and apoptosis in colorectal cancer [25]. No effect 
on cell viability upon IFNγ was found in JAK1 mutant 
gynecological cell lines [10]. In conclusion, we confirmed 
the remarkably high frequency of JAK1 mutations and 
associations with impaired upregulation of antigen 
presenting machinery components in MSI endometrial 




DNA analysis and immunohistochemical staining 
was performed on a study cohort of 181 endometrial 
cancers with endometrioid histology, treated at the 
University Medical Center Groningen between 1985-2004 
or at the University Medical Center Leiden between 2000-
2013. Classification and grading was done according to 
the World Health Organization criteria and staging was 
according to FIGO guidelines (2009). No follow-up data 
was available for this study cohort.
To validate our findings regarding the JAK1 
mutation frequency in MSI endometrial cancer, an 
independent cohort of 198 MSI early-stage endometrial 
cancers derived from the randomized PORTEC-1 and -2 
clinical trials was used [19, 20]. To estimate the impact of 
JAK1 mutation on survival the same cohort of 198 MSI 
endometrial cancers was used [26].
MSI and JAK1 mutation status
DNA was isolated as previously described [27]. 
The MSI status of each tumor was determined using the 
Promega MSI analysis system (version 1.2, Promega). 
Tumors with instability in at least two markers were 
defined as being high-frequency MSI whereas those 
showing no instability or instability in one marker 
were classified as being stable (MSS). JAK1 frameshift 
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mutations (k142fs, p430fs, k860fs) were detected by 
Sanger sequencing. The following primers were used: exon 
5-F: 5’-GTCACATCTGGGTCCCCTTTGCCAC-3’, exon 
5-R: 5’-CACAAACTCCAGCTTCTCCTGGGC-3’, exon 
9-F: 5’-GTCGAGGAGGCCTTG TCCTTTGTGTC-3’, 
exon 9-R: 5’-ACACGGGCTCTCTGCACACC-3’, exon 
19-F: 5’-GTATCGACTGCCTTTCACTCTG-3’, exon 19-
R: 5’-CTTACCTCTCCCAAGTCACGG-3’.
Immunohistochemistry
Formalin-fixed paraffin embedded 4-μm tissue 
sections of MSI endometrial cancers (n=58) with 
sufficient tumor tissue were immunohistochemically 
stained for expression of LMP7, TAP1, HLA class 
I (HCA2 and HC10) and CD8 (marker of cytotoxic 
T-cells). Sections were deparaffinized in xylene, 
rehydrated in graded concentration of ethanol and 
microwave antigen retrieval was performed in 10 
mM citrate pH 6.0 (LMP7, TAP1), 10 mM Tris/1 
mM EDTA pH 9.0 (LMP7, TAP1, HCA2, HC10 and 
CD8) before staining. Endogenous peroxidase was 
blocked by incubation in a 0.3% hydrogen peroxide 
solution. LMP7 and TAP1 were stained using anti-
LMP7 mouse monoclonal 1B3 (Novus Biologicals) 
and anti-TAP1 rabbit polyclonal H300 (Santa Cruz) 
as primary antibodies by incubation overnight at 4°C 
(dilution 1:100 and 1:50 respectively). HLA class I was 
stained using HCA2 and HC10 as previously described 
[16]. Antigen-antibody reactions were visualized 
using 3.3’-diaminobenzidine (DAB) and slides were 
counterstained with hematoxylin.
Evaluation of immunohistochemistry
Two observers blinded to clinicopathological 
features, MSI and JAK1 mutation status independently 
evaluated the stained slides. Expression of LMP7 
and TAP1 was scored using a semiquantative scale as 
described previously [13, 28]. This score is based on the 
percentage of cells stained and the intensity of staining. 
The percentage of cells was scored on a 6 point scale with 
0 for 0%, 1 for 1-5%, 2 for 5-25%, 3 for 25-50%, 4 for 
50-75% and 5 for 75-100%. The intensity was scored on 
a 4 point scale with 0 indicating absence of staining and 3 
indicating strong staining. The expression of LMP7, and 
TAP1 was categorized in impaired (score 0-2), normal 
(score 3-6) and upregulated (score 7-8) expression. 
For analysis of HLA class I expression, the percentage 
of tumor cells with membranous HCA2 and HC10 
staining was quantified as previously described [16]. 
The expression of HLA class I was defined as follows: 
impaired HLA class I expression: less than 5% of tumor 
cells expressing both HCA2 and HC10, normal HLA class 
I expression; less than 5% of tumor cells expressing either 
of the markers, and upregulated HLA class I expression: 
5% or more expressing both markers.
The number of CD8-positive T-cells was calculated 
using the average number of stained cells in 8 fields at 
40x magnification. The average was calculated for four 
locations: intraepithelial at the tumor center, intraepithelial 
at the invasive margin, intrastromal in the tumor center 
and intrastromal at the invasive margin. For statistical 
analysis values for CD8 were dichotomized using the 
median as a cut off.
The cancer genome atlas (TCGA) RNAseq data
Details of the TCGA RNAseq analysis have been 
previously reported [1]. Level 3 RSEM normalized RNA 
data profiled using the Illumina HiSeq RNAseq v2 were 
retrieved at the TCGA data portal. MSI events, differences 
in length of microsatellites, in 30 MSI EC patients were 
reported by Kim et al [4]. In total, 25 MSI endometrial 
cancers with both RSEM normalized and DNA slippage 
event data were informative for analysis.
Statistical analysis
JAK1 mutation status was compared between 
cases with and without microsatellite instability using 
Chi-square tests. Similarly, Chi-square tests were used 
to detect differences in expression of LMP7, TAP1, 
HLA class I and number of CD8-positive T-cells below 
or above the median for cases with and without JAK1 
mutation. The non-parametric Mann-Whitney test 
was used for all comparisons of continuous data and 
Spearman’s rho to analyze correlation between variables. 
RNAseq data was visualized by unsupervised clustering 
using RStudio.
To evaluate the impact of JAK1 mutation status 
on survival in MSI endometrial cancer patients that 
participated in the randomized PORTEC-1 and -2 clinical 
trials, time-to-event analyses were calculated from the date 
of randomization to date of recurrence (vaginal, pelvic 
and/or distant recurrence) or to date of death (overall 
survival); patients who were alive and without recurrence 
were censored at the date of last follow-up. Survival 
curves were calculated using the Kaplan—Meier method 
with log-rank test.
Analyses were performed using SPSS (v20, IBM 
statistics, Chicago, IL, USA).
ACKNOWLEDGMENTS
This study was supported by the Dutch Cancer 
Society (UL2012-5719). The PORTEC-1 and -2 trials 
were also supported by Dutch Cancer Society grants. We 
acknowledge all members of the PORTEC study group and 
the many patients who participated in the PORTEC trials.
Oncotarget39892www.impactjournals.com/oncotarget
CONFLICTS OF INTEREST




1. Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, 
Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, 
Laird PW, Ding L, et al. Integrated genomic characterization 
of endometrial carcinoma. Nature. 2013; 497:67-73.
2. Imai K and Yamamoto H. Carcinogenesis and microsatellite 
instability: the interrelationship between genetics and 
epigenetics. Carcinogenesis. 2008; 29:673-80.
3. Duval A, Reperant M, Compoint A, Seruca R, Ranzani GN, 
Iacopetta B and Hamelin R. Target gene mutation profile 
differs between gastrointestinal and endometrial tumors with 
mismatch repair deficiency. Cancer Res. 2002; 62:1609-12.
4. Kim TM, Laird PW and Park PJ. The landscape of 
microsatellite instability in colorectal and endometrial 
cancer genomes. Cell. 2013; 155:858-68.
5. Ferreira AM, Tuominen I, Sousa S, Gerbens F, van Dijk-
Bos K, Osinga J, Kooi KA, Sanjabi B, Esendam C, Oliveira 
C, Terpstra P, Hardonk M, van der Sluis T, et al. New target 
genes in endometrial tumors show a role for the estrogen-
receptor pathway in microsatellite-unstable cancers. Hum 
Mutat. 2014; 35:1514-23.
6. Myeroff LL, Parsons R, Kim SJ, Hedrick L, Cho KR, 
Orth K, Mathis M, Kinzler KW, Lutterbaugh J and Park 
K. A transforming growth factor beta receptor type II 
gene mutation common in colon and gastric but rare in 
endometrial cancers with microsatellite instability. Cancer 
Res. 1995; 55:5545-47.
7. Thomas SJ, Snowden JA, Zeidler MP and Danson SJ. 
The role of JAK/STAT signalling in the pathogenesis, 
prognosis and treatment of solid tumours. Br J Cancer. 
2015; 113:365-71.
8. Aaronson DS and Horvath CM. A road map for those who 
don’t know JAK-STAT. Science. 2002; 296: 1653-55.
9. Murray PJ. The JAK-STAT signaling pathway: input and 
output integration. J Immunol. 2007; 178:2623-29.
10. Ren Y, Zhang Y, Liu RZ, Fenstermacher DA, Wright 
KL, Teer JK and Wu J. JAK1 truncating mutations in 
gynecologic cancer define new role of cancer-associated 
protein tyrosine kinase aberrations. Sci Rep. 2013; 3: 3042.
11. Vesely MD, Kershaw MH, Schreiber RD and Smyth MJ. 
Natural innate and adaptive immunity to cancer. Annu Rev 
Immunol. 2011; 29: 235-71.
12. Schreiber RD, Old LJ and Smyth MJ. Cancer 
immunoediting: integrating immunity’s roles in cancer 
suppression and promotion. Science. 2011; 331:1565-70.
13. Bijen CB, Bantema-Joppe EJ, de Jong RA, Leffers N, 
Mourits MJ, Eggink HF, van der Zee AG, Hollema H, de 
Bock GH and Nijman HW. The prognostic role of classical 
and nonclassical MHC class I expression in endometrial 
cancer. Int J Cancer. 2010; 126:1417-27.
14. de Jong RA, Boerma A, Boezen HM, Mourits MJ, Hollema 
H and Nijman HW. Loss of HLA class I and mismatch 
repair protein expression in sporadic endometrioid 
endometrial carcinomas. Int J Cancer. 2012; 131:1828-36.
15. Yakabe K, Murakami A, Nishimoto Y, Kajimura T, Sueoka 
K and Sugino N. Clinical implications of human leukocyte 
antigen class I expression in endometrial cancer. Mol Clin 
Oncol. 2015; 3:1285-90.
16. van Gool IC, Eggink FA, Freeman-Mills L, Stelloo E, 
Marchi E, de Bruyn M, Palles C, Nout RA, de Kroon CD, 
Osse EM, Klenerman P, Creutzberg CL, Tomlinson IP, et al. 
POLE Proofreading Mutations Elicit an Antitumor Immune 
Response in Endometrial Cancer. Clin Cancer Res. 2015; 
21:3347-55.
17. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, 
Eyring AD, Skora AD Luber BS, Azad NS, Laheru D, 
Biedrzycki B, Donehower TC, et al. PD-1 Blockade in 
Tumors with Mismatch-Repair Deficiency. N Engl J Med. 
2015; 372:2509-20.
18. Shin D, Garcia-Diaz A, Zaretsky J, Escuin-Ordinas H, 
Hu-Lieskovan S, Berent-Maoz B, Comin-Anduix B and 
Ribas A. Innate resistance of PD-1 blockade through loss of 
function mutations in JAK resulting in inability to express 
PD-L1 upon interferon exposure. J Immunother Cancer. 
2015; 3: P311.
19. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, 
Jobsen JJ, Warlam-Rodenhuis CC, De Winter KA, Lutgens 
LC, van den Bergh AC, Steen-basanik E, Beerman H 
and van Lent M. Surgery and postoperative radiotherapy 
versus surgery alone for patients with stage-1 endometrial 
carcinoma: multicentre randomised trial. PORTEC Study 
Group. Post Operative Radiation Therapy in Endometrial 
Carcinoma. Lancet. 2000; 355:1404-11.
20. Nout RA, Smit VT, Putter H, Jurgenliemk-Schulz IM, 
Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Mens 
JW, Slot A, Kroese MC, van Bunningen BN, Ansink AC, 
van Putten WL, et al. Vaginal brachytherapy versus pelvic 
external beam radiotherapy for patients with endometrial 
cancer of high-intermediate risk (PORTEC-2): an open-
label, non-inferiority, randomised trial. Lancet. 2010; 
375:816-23.
21. Cabrera CM, Jimenez P, Cabrera T, Esparza C, Ruiz-
Cabello F and Garrido F. Total loss of MHC class I in 
colorectal tumors can be explained by two molecular 
pathways: beta2-microglobulin inactivation in MSI-positive 
tumors and LMP7/TAP2 downregulation in MSI-negative 
tumors. Tissue Antigens. 2003; 61:211-19.
22. Kang JK, Yoon SJ, Kim NK and Heo DS. The expression of 
MHC class I, TAP1/2, and LMP2/7 gene in human gastric 
cancer cell lines. Int J Oncol. 2000;16:1159-63.
Oncotarget39893www.impactjournals.com/oncotarget
23. Corthay A, Skovseth DK, Lundin KU, Rosjo E, Omholt H, 
Hofgaard PO, Haraldsen G and Bogen B. Primary antitumor 
immune response mediated by CD4+ T cells. Immunity. 
2005; 22:371-83.
24. Kloor M, Michel S and von Knebel DM. Immune evasion 
of microsatellite unstable colorectal cancers. Int J Cancer. 
2010; 127:1001-10.
25. Xiong H, Zhang ZG, Tian XQ, Sun DF, Liang QC, Zhang 
YJ, Lu R, Chen YX and Fang JY. Inhibition of JAK1, 2/
STAT3 signaling induces apoptosis, cell cycle arrest, and 
reduces tumor cell invasion in colorectal cancer cells. 
Neoplasia. 2008; 10:287-97.
26. Stelloo E, Nout RA, Osse EM, Jurgenliemk-Schulz 
IJ, Jobsen JJ, Lutgens LC, van der Steen-Basanik EM, 
Nijman HW, Putter H, Bosse T, Creutzberg CL, Smit 
VT. Improved risk assessment by integrating molecular 
and clinicopathological factors in early-stage endometrial 
cancer - combined analysis of PORTEC cohorts. Clin 
cancer res. 2016.
27. Stelloo E, Bosse T, Nout RA, MacKay HJ, Church DN, 
Nijman HW, Leary A, Edmondson RJ, Powell ME, Crosbie 
EJ, Kitchener HC, Mileshkin L, Pollock PM, et al. Refining 
prognosis and identifying targetable pathways for high-risk 
endometrial cancer; a TransPORTEC initiative. Mod Pathol. 
2015; 28:836-44.
28. Ruiter DJ, Ferrier CM, van Muijen GN, Henzen-Logmans 
SC, Kennedy S, Kramer MD, Nielsen BS and Schmitt 
M. Quality control of immunohistochemical evaluation 
of tumour-associated plasminogen activators and related 
components. European BIOMED-1 Concerted Action on 
Clinical Relevance of Proteases in Tumour Invasion and 
Metastasis. Eur J Cancer. 1998; 34:1334-40.
